Overview
The Seventeenth Meeting of the World Health Organization (WHO) South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) was held from 23 to 25 September 2026 at the WHO Regional Office for South-East Asia in New Delhi, India. The meeting brought together SEAR-ITAG members, representatives of Member States and national immunization technical advisory groups (NITAGs), WHO experts and partner organizations to assess regional and country progress, review emerging evidence and provide independent technical guidance for immunization policy and programme implementation. The meeting reviewed implementation of the Regional Vaccine Implementation Plan (RVIP) 2022–2026 and considered priorities for the next strategic cycle, including the development of the RVIP 2027–2030.
The meeting recognized important regional achievements, including strong routine immunization performance in many countries, sustained wild poliovirus-free status and maternal and neonatal tetanus elimination, progress towards rubella elimination and hepatitis B control, expanding access to new and underused vaccines and increased use of digital and targeted approaches. Regional coverage with the third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3) and the first dose of measles-containing vaccine (MCV1) reached 94% and 96%, respectively, in 2025. The estimated number of zero-dose children declined to approximately 1.2 million, reflecting substantial recovery of immunization services and renewed efforts to identify and reach missed children.
The Region also continued to broaden protection across the life course through the introduction and scale-up of vaccines against human papillomavirus, pneumococcal disease, rotavirus and typhoid, alongside strengthened school-based, maternal and primary health-care delivery platforms. By 2025, the regional breadth of protection (BOP) had reached 85%, and immunization during 2021–2025 was estimated to have averted more than 4.2 million future deaths. The meeting emphasized that new vaccine introductions should be accompanied by sustainable vaccine delivery arrangements, reliable supply, appropriate safety preparedness, strong monitoring and mechanisms to reach populations beyond infancy, including adolescents, pregnant women, adults and older people.